Kenneth Pienta Net Worth

The estimated Net Worth of Kenneth Pienta is at least $1.44 Mille dollars as of 15 March 2021. Kenneth Pienta owns over 13,439 units of Cue Biopharma Inc stock worth over $1,439 and over the last 12 years he sold CUE stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Cue Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kenneth Pienta CUE stock SEC Form 4 insiders trading

Kenneth has made over 6 trades of the Cue Biopharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 13,439 units of CUE stock worth $67,195 on 15 March 2021.

The largest trade he's ever made was exercising 20,274 units of Cue Biopharma Inc stock on 16 February 2021 worth over $64,471. On average, Kenneth trades about 4,562 units every 182 days since 2013. As of 15 March 2021 he still owns at least 2,439 units of Cue Biopharma Inc stock.

You can see the complete history of Kenneth Pienta stock trades at the bottom of the page.

Kenneth Pienta biography

Dr. Kenneth J. Pienta M.D. serves as Chief Medical Officer of the Company. He is currently the Donald S. Coffey Professor of Urology and Professor of Oncology and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine and serves as the Director of Research for the Brady Urological Institute. He previously served as a director of Curis from March 2013 to May 2017. From 1995 to 2013, Dr. Pienta was the Director of the Prostate Specialized Program of Research Excellence (SPORE) at The University of Michigan. He is a two-time American Cancer Society Clinical Research Professor Award recipient, is the author of more than 450 peer-reviewed articles, and has been the principal investigator on numerous local and national clinical trials. Dr. Pienta received a B.A. and an M.D. from the Johns Hopkins University.

How old is Kenneth Pienta?

Kenneth Pienta is 60, he's been the Chief Medical Officer of Cue Biopharma Inc since 2017. There are 6 older and 11 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.

What's Kenneth Pienta's mailing address?

Kenneth's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 21 ERIE STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Cue Biopharma Inc

Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher e Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.

What does Cue Biopharma Inc do?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Complete history of Kenneth Pienta stock trades at Curis Inc e Cue Biopharma Inc

Cue Biopharma Inc executives and stock owners

Cue Biopharma Inc executives and other stock owners filed with the SEC include:

• Anish Suri,
  President, Chief Scientific Officer
• Daniel Passeri,
  Chief Executive Officer, Director
• Daniel R. Passeri M.Sc., MSc., J.D.,
  CEO & Director
• Colin Sandercock,
  Senior Vice President, General Counsel, Secretary
• Dr. Anish Suri Ph.D.,
  Pres & Chief Scientific Officer
• Kerri-Ann Millar,
  Chief Financial Officer
• Aaron Fletcher,
  Independent Director
• Barry Simon,
  Independent Director
• Peter Kiener,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Frank Morich,
  Independent Chairman of the Board
• Cameron Gray,
  Independent Director
• Tamar Howson,
  Director
• Kenneth Pienta,
  Chief Medical Officer
• Kerri-Ann Millar,
  Chief Financial Officer
• Dr. Kenneth J. Pienta,
  Acting Chief Medical Officer
• Dr. Ronald D. Seidel III, Ph.D.,
  Co-Founder
• Dr. Matteo Levisetti M.D.,
  Sr. VP of Clinical Devel.
• Dr. Ronald D. Seidel III,
  Exec. VP and Head of R&D
• Colin G. Sandercock J.D., MSE,
  Sr. VP, Gen. Counsel & Sec.
• George B. Zavoico Ph.D.,
  VP of Investor Relations & Corp. Devel.
• Dr. Steven C. Almo,
  Co-Founder and Chairman of Scientific & Clinical Advisory Board
• Dr. Rodolfo J. Chaparro,
  Co-Founder & Sr. Advisor
• Bethany Mancilla,
  SVP and Chief Business Officer
• Ronald D. Iii Seidel,
  EVP, Head of R&D
• Christopher A Marlett,
  Director
• Anthony Digiandomenico,
  Director
• Rodolfo Chaparro,
  EVP, Head of Immunology
• Steven L Mcknight,
  Director
• Patricia Nasshorn,
  Chief Business Officer
• Matteo Levisetti,
  Chief Medical Officer
• Michael J Fox,
  
• Pamela Garzone,
  
• Patrick Verheyen,
  
• Lucinda Warren,
  CHIEF BUSINESS OFFICER